Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 4:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 17,535 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Study Agent Clear all
Completed Phase 1 Interventional

A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine

NCT03755713
View directory record Official record
Conditions
Peanut Allergy
Interventions
ASP0892, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Little Rock, Arkansas • Mountain View, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 29, 2026, 4:43 PM EDT
Active, not recruiting Phase 3 Interventional

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

NCT04592913
View directory record Official record
Conditions
Gastrointestinal Neoplasms, Esophagogastric Junction
Interventions
Durvalumab, FLOT chemotherapy
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 200 Years
Enrollment
957 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
16
States / cities
Duarte, California • Los Angeles, California • Sylmar, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 29, 2026, 4:43 PM EDT
Completed Phase 1Phase 2 Interventional

Rituxan and BEAM With Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma

NCT00572013
View directory record Official record
Conditions
Lymphoma
Interventions
Rituxan, BEAM, Autologous stem cell transplant
Drug · Procedure
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 29, 2026, 4:43 PM EDT
Completed No phase listed Interventional Accepts healthy volunteers Results available

RHA® 3 Versus Restylane-L® for Lip Augmentation

NCT04540913
View directory record Official record
Conditions
Lip Augmentation, Lip
Interventions
RHA 3, Restylane-L
Device
Lead sponsor
Teoxane SA
Industry
Eligibility
22 Years and older
Enrollment
202 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Bradenton, Florida
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 29, 2026, 4:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of an Arabinogalactan Product

NCT04005924
View directory record Official record
Conditions
Postprandial Blood Glucose
Interventions
arabinogalactan
Other
Lead sponsor
Biofortis, Merieux NutriSciences
Industry
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 29, 2026, 4:43 PM EDT
Recruiting Phase 3 Interventional

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

NCT06136624
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
Opevesostat, Abiraterone acetate, Enzalutamide, Hydrocortisone, Fludrocortisone acetate, Prednisone, Dexamethasone
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
48
States / cities
Orange, California • Palo Alto, California • Riverside, California + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 29, 2026, 4:43 PM EDT
Not yet recruiting Not applicable Interventional

Open-Label Clinical Trial Evaluating the Impact of a Multi-Strain Commensal Probiotic Dietary Supplement on Gastrointestinal Microbiota Composition, Functional Gastrointestinal Markers, and Gastrointestinal Symptoms

NCT07720362
View directory record Official record
Conditions
Gastrointestinal, Microbiota
Interventions
Complete Commensal Probiotic
Dietary Supplement
Lead sponsor
OvationLab
Network
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 29, 2026, 4:43 PM EDT
Completed Phase 1 Interventional

Trial of Adoptive Immunotherapy With TRACT to Prevent Rejection in Living Donor Kidney Transplant Recipients

NCT02145325
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Expanded Tregs
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 29, 2026, 4:43 PM EDT
Not yet recruiting Phase 2Phase 3 Interventional

PRP Versus NP Injections for Chronic Discogenic Low Back Pain

NCT07895225
View directory record Official record
Conditions
Discogenic Low Back Pain
Interventions
Platelet-Rich Plasma (PRP) Injection, Nucleus Pulposus (NP) Injection
Biological
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years to 100 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 29, 2026, 4:43 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD

NCT03062540
View directory record Official record
Conditions
PTSD
Interventions
TNX-102 SL, Placebo SL Tablet
Drug
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
44
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 29, 2026, 4:43 PM EDT
Completed Phase 4 Interventional Results available

NMDA Antagonists in Bipolar Depression

NCT01833897
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Standard of Care, Ketamine, D-cycloserine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Oct 29, 2026, 4:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Open Label Single Arm Prebiotic Pilot Trial SR001

NCT07127120
View directory record Official record
Conditions
PARKINSON DISEASE (Disorder)
Interventions
Prebiotic fiber blend
Dietary Supplement
Lead sponsor
Sorridi Therapeutics
Industry
Eligibility
60 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Northbrook, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 29, 2026, 4:43 PM EDT
Completed Phase 2 Interventional

A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include Amprenavir

NCT00002423
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Lamivudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
8
States / cities
San Francisco, California • Washington D.C., District of Columbia • Altamonte Springs, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 29, 2026, 4:43 PM EDT
Recruiting Phase 2 Interventional

Open-Label Extension Protocol to SNK01-AD01 Study

NCT07228078
View directory record Official record
Conditions
Alzheimer Disease
Interventions
SNK01
Biological
Lead sponsor
NKGen Biotech, Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Oct 29, 2026, 4:43 PM EDT
Completed Phase 1Phase 2 Interventional

AAVRh.10 Administered to Children With Late Infantile Neuronal Ceroid Lipofuscinosis

NCT01414985
View directory record Official record
Conditions
Late Infantile Neuronal Ceroid Lipofuscinosis, Batten Disease
Interventions
AAVrh.10CUCLN2
Biological
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
3 Years to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Oct 29, 2026, 4:43 PM EDT
Completed Phase 3 Interventional Results available

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.

NCT04625725
View directory record Official record
Conditions
COVID-19
Interventions
AZD7442, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 120 Years
Enrollment
5,197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
60
States / cities
Birmingham, Alabama • Tempe, Arizona • Little Rock, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced Oct 29, 2026, 4:43 PM EDT
Completed Not applicable Interventional

AM for Refractory Achilles Tendinopathy

NCT06172218
View directory record Official record
Conditions
Achilles Tendinopathy
Interventions
Flo, Saline
Other
Lead sponsor
North Park Podiatry
Other
Eligibility
18 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 29, 2026, 4:43 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Evaluating the Pharmacokinetics of Oregano and Potential Oregano-drug Interactions Using a Drug Cocktail Approach

NCT06693960
View directory record Official record
Conditions
Interaction
Interventions
Oregano, Drug cocktail
Dietary Supplement · Drug
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 29, 2026, 4:43 PM EDT
Completed No phase listed Observational

A Prospective Safety Follow Up Study Of Subjects Enrolled In Study A4321001 And Who Have Received Drug Product

NCT00471224
View directory record Official record
Conditions
Siderosis
Interventions
Observational Trial
Other
Lead sponsor
Pfizer
Industry
Eligibility
55 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Boston, Massachusetts • Charlotte, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2011 · Synced Oct 29, 2026, 4:43 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function

NCT03618420
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Nephropathy, Diabetic Nephropathies, Juvenile Diabetes, Diabetes Mellitus Complication, Autoimmune Diabetes, Type 1 Diabetes Mellitus
Interventions
Aminohippurate Sodium Inj 20%, Iohexol Inj 300 mg/mL
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Oct 29, 2026, 4:43 PM EDT
Completed Phase 3 Interventional

A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease

NCT00675623
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Dimebon, Placebo
Drug
Lead sponsor
Medivation, Inc.
Industry
Eligibility
50 Years and older
Enrollment
598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
28
States / cities
Phoenix, Arizona • Costa Mesa, California • Fresno, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Oct 29, 2026, 4:43 PM EDT
Completed No phase listed Observational

Correlate of Surface Electroencephalogram (EEG) With Implanted EEG Recordings (ECOG)

NCT03629743
View directory record Official record
Conditions
Anesthesia
Interventions
EEG, ECOG
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 29, 2026, 4:43 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

The ICEC Cluster Trial: Integrated Community Engagement Collaborative for Youth Substance Use Prevention in Rural America

NCT07843576
View directory record Official record
Conditions
Substance Use (Drugs, Alcohol), Tobacco Use, Adolescent Substance Use
Interventions
Integrated Community Engagement Collaborative, School-Based Data Collection and Reporting without Network Coordinator Support
Other
Lead sponsor
West Virginia University
Other
Eligibility
10 Years and older
Enrollment
25,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 29, 2026, 4:43 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of SGN1 in Patients With Advanced Solid Tumor

NCT05038150
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
SGN1
Drug
Lead sponsor
Guangzhou Sinogen Pharmaceutical Co., Ltd
Other
Eligibility
18 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Gilbert, Arizona • Orange, California • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Oct 29, 2026, 4:43 PM EDT